SCHEMBL168574

SCHEMBL168574

Cn1cc(-c2cc(C(=O)Nc3cccc(Cl)c3)c(OCc3ccccc3)cc2CN2CCOCC2)cn1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MET P08581 2/20 0.51
LRRK2 Q5S007 7/20 0.51
PTGER1 P34995 1/20 0.49
TRPV4 Q9HBA0 1/20 0.48
HTT P42858 1/20 0.45
RECQL P46063 1/20 0.45
CYP3A4 P08684 1/20 0.45
SLCO1B1 Q9Y6L6 1/20 0.45
CCNC P24863 2/20 0.44
CDK8 P49336 2/20 0.44
KCNH2 Q12809 1/20 0.44
GSK3B P49841 1/20 0.44
DYRK1A Q13627 1/20 0.44
CDK19 Q9BWU1 1/20 0.44
AURKA O14965 1/20 0.43
AURKB Q96GD4 1/20 0.43
GAA P10253 1/20 0.42
FSCN1 Q16658 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL168720 0.89 LRRK2 (0.66) METLRRK2CYP3A4SLCO1B1CCNC
SCHEMBL10192559 0.87 LRRK2 (0.60) LRRK2CYP3A4SLCO1B1KCNH2
SCHEMBL168123 0.84 LRRK2 (0.60) METLRRK2PTGER1TRPV4HTT
SCHEMBL167588 0.83 LRRK2 (0.67) METLRRK2CCNCCDK8GSK3B
SCHEMBL256499 0.82 CNR1 (0.47) METLRRK2TRPV4HTTCYP3A4
SCHEMBL165468 0.82 LRRK2 (0.59) METLRRK2PTGER1TRPV4HTT
SCHEMBL165714 0.81 LRRK2 (0.53) METLRRK2CYP3A4GSK3BDYRK1A
SCHEMBL176025 0.80 LRRK2 (0.67) METLRRK2CCNCCDK8GSK3B
SCHEMBL257050 0.79 LRRK2 (0.51) METLRRK2PTGER1CYP3A4SLCO1B1
SCHEMBL10192760 0.77 LRRK2 (0.54) LRRK2CYP3A4SLCO1B1CCNCCDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611772-B1 2-(BENZYLOXY)BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2014-09-24 EP claimed
US-9365551-B2 2-(benzyloxy) benzamides as LRRK2 kinase inhibitors GLAXO GROUP LIMITED (GB) 2016-06-14 US disclosed
US-9365551-B2 2-(benzyloxy) benzamides as LRRK2 kinase inhibitors GLAXO GROUP LIMITED (GB) 2016-06-14 US disclosed
EP-2611772-B1 2-(BENZYLOXY)BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2014-09-24 EP disclosed
EP-2611772-B1 2-(BENZYLOXY)BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2014-09-24 EP disclosed
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-08-29 US disclosed
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-08-29 US disclosed
EP-2611772-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2013-07-10 EP disclosed
WO-2012028629-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS LRRK2, PARK7, BRSK2 MET 3646/4885LRRK2 1/4885PTGER1 4158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.